Esperion Therapeutics, Inc.

ESPR

US29664W1053

Pharmaceuticals

Delayed Nasdaq Other stock markets 01:23:59 30/05/2024 am IST			5-day change	1st Jan Change
2.168 ^USD	+3.21%		-9.03%	-27.59%

22/05	Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	CI
20/05	Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	MT

Richard B. Bartram to Step Down as Principal Accounting Officer of Esperion Therapeutics, Inc., Effective as of April 8, 2022

March 16, 2022 at 01:31 am IST

On March 15, 2022, Esperion Therapeutics, Inc. announced that Richard B. Bartram was stepping down from his positions as Principal Accounting Officer of the Company, effective as of April 8, 2022. Mr. Bartram's decision did not result from a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Latest news about Esperion Therapeutics, Inc.

Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	22/05	CI
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	20/05	MT
Transcript : Esperion Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	16/05
Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	07/05	MT
Top Premarket Gainers	07/05	MT
Transcript : Esperion Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M	07/05	MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01	07/05	MT
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	25/03	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	25/03	MT
Transcript : Esperion Therapeutics, Inc. - Special Call	25/03
Top Premarket Gainers	25/03	MT
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	23/03	CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	23/03	MT
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet	23/03	DJ
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	22/03	MT
Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications	22/03	DJ
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination	22/03	CI
Transcript : Esperion Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	27/02
North American Morning Briefing : Stock Futures -2-	27/02	DJ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q4 Revenue $32.3M, vs. Street Est of $28.7M	27/02	MT
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02	CI
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	19/01	MT

Chart Esperion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Esperion Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.1 USD

Average target price

7.414 USD

Spread / Average Target

+253.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ESPERION THERAPEUTICS, INC.	-27.59%	40Cr
ELI LILLY AND COMPANY	+39.08%	73TCr
NOVO NORDISK A/S	+30.57%	59TCr
JOHNSON & JOHNSON	-7.88%	35TCr
MERCK & CO., INC.	+15.55%	32TCr
ABBVIE INC.	-0.31%	27TCr
ASTRAZENECA PLC	+12.55%	24TCr
NOVARTIS AG	+6.65%	20TCr
ROCHE HOLDING AG	-6.09%	20TCr
PFIZER, INC.	-3.23%	16TCr

Other Pharmaceuticals

Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Pharmaceuticals

Richard B. Bartram to Step Down as Principal Accounting Officer of Esperion Therapeutics, Inc., Effective as of April 8, 2022

EPS Revisions